| Literature DB >> 34895263 |
Oliver Schilling1, Tamás Radovits2, Bálint András Barta3,4,5, Mihály Ruppert2, Klemens Erwin Fröhlich1,6,7, Miguel Cosenza-Contreras1,6,8, Attila Oláh2, Alex Ali Sayour2, Krisztián Kovács9, Gellért Balázs Karvaly9, Martin Biniossek10, Béla Merkely2.
Abstract
BACKGROUND: Reduced cardiovascular risk in premenopausal women has been the focus of research in recent decades. Previous hypothesis-driven experiments have highlighted the role of sex hormones on distinct inflammatory responses, mitochondrial proteins, extracellular remodeling and estrogen-mediated cardioprotective signaling pathways related to post-ischemic recovery, which were associated with better cardiac functional outcomes in females. We aimed to investigate the early, sex-specific functional and proteomic changes following myocardial ischemia in an unbiased approach.Entities:
Keywords: Estrogens; Left ventricular function; Myocardial ischemia; Proteomic changes; Sex differences
Mesh:
Year: 2021 PMID: 34895263 PMCID: PMC8666068 DOI: 10.1186/s12967-021-03164-y
Source DB: PubMed Journal: J Transl Med ISSN: 1479-5876 Impact factor: 5.531
Fig. 1Experimental protocol and assessment of effect of isoproterenol. A Study design. B Heart rates recorded 2 min after injection of isoproterenol showed a comparable increase due to β-adrenergic activation in both males and females. C Increments in heart weight normalized to tibia length indicated a buildup of edema in both sexes. D The percentage of the area of intact myofibers on histological slides of the myocardium declined due to isoproterenol therapy in both sexes compared to controls. E The percentage of picrosirius red stained area was not significantly changed in response to ischemia at the end of the experimental period. F Representative photomicrographs of hematoxylin & eosin stained slides demonstrate diffuse necrotic areas (arrows) embedded within healthy areas of the myocardium after isoproterenol-induced ischemia. Further images (second row) demonstrate how after H&E color deconvolution the eosin color component can be used to quantify the relative area of intact myofibers in the myocardium. First, the overall area of the myocardium is detected. Areas devoid of any myocardial tissue are outlined with yellow and are excluded from the calculation of the overall myocardial area. Then careful thresholding on the eosin color component can identify viable cardiomyocytes with intact myofibrillar structures. These areas (colored red in the software) are then used for the calculation of intact myofibrillar areas which are inversely proportional to and thus are an indirect measure of the extent of myocardial damage, myocardial necrosis. G: representative photomicrographs of picrosirius stained slides. Statistical significance of post-hoc test compared to same sex control is highlighted as follows: *P < 0.05, **P < 0.01, ***P < 0.001. M-Co: male control; M-Isch: male ischemic; F-Co: female control; F-Isch: female ischemic; HR: heart rate; HW/TL: heart weight normalized to tibia length
Fig. 2Assessment of systolic and diastolic function. The decline of systolic function was more pronounced in males, while diastolic function deteriorated to a greater degree in females after isoproterenol treatment. A, B Contractility as assessed by EF and PRSW markedly decreased in males after ischemia. D Accordingly, MAP significantly decreased in males as well. E The observed deterioration of systolic function of males was underlain by a marked decline in cardiac efficiency. C Marked increase in Tau indicated a more pronounced worsening of active relaxation in females. F Diastolic stiffness increased only in females as determined by EDPVR. Statistical significance of post hoc test compared to same-sex control is highlighted as follows: *P < 0.05, **P < 0.01, ***P < 0.001. M-Co: male control; M-Isch: male ischemic; F-Co female control; F-Isch: female ischemic; EF: ejection fraction; PRSW: preload recruitable stroke work; MAP: mean arterial pressure; EDPVR: slope of the LV end-diastolic pressure–volume relationship
Basic hemodynamic characteristics of experimental groups
| Parameter | M-Co | M-Isch | F-Co | F-Isch |
|---|---|---|---|---|
| BW (g) | 205.1 ± 3.3 | 195.2 ± 5.6 | 189.8 ± 2.2 | 193.2 ± 3 |
| SABP (mmHg) | 136.2 ± 3.5 | 103.4 ± 5.0** | 129.7 ± 7.4 | 114.6 ± 7.2 |
| DABP (mmHg) | 105.4 ± 1.9 | 81.52 ± 4.7* | 104.22 ± 4.9 | 91.6 ± 5.3 |
| MAP (mmHg) | 115.2 ± 2.2 | 88.8 ± 4.7* | 112.7 ± 5.7 | 99.2 ± 5.9 |
| HR (bpm) | 419.2 ± 11.2 | 408.9 ± 7.8 | 416.5 ± 12.1 | 386.3 ± 9.2 |
| LVESV (µL) | 53.5 ± 3.3 | 114.2 ± 21.0 | 67.7 ± 11.5 | 89.7 ± 12.6 |
| LVEDV (µL) | 154.6 ± 9.2 | 207.3 ± 20.7 | 195.9 ± 14.0 | 189.4 ± 17.4 |
| LVESP (mmHg) | 124.8 ± 3.4 | 100.1 ± 3.5* | 128.8 ± 5.3 | 103.6 ± 6.0** |
| LVEDP (mmHg) | 11.0 ± 1.1 | 11.2 ± 0.9 | 8.6 ± 0.8 | 13.6 ± 1.7* |
| SV (µL) | 117.5 ± 11.3 | 111.8 ± 5.6 | 141.6 ± 5.1 | 112. ± 11.1 |
| CO (µL/min) | 48,694 ± 4106 | 45,785 ± 2540 | 58,968 ± 2678 | 43,175 ± 4240* |
| SW (mmHg*μL) | 14,316 ± 1775 | 9455 ± 798* | 15,111 ± 800 | 10,626 ± 1234 |
| dP/dtmax (mmHg/s) | 7458 ± 341 | 6612 ± 293 | 8636 ± 420 | 7531 ± 402 |
| dP/dtmax-EDV (mmHg/(s*μL)) | 64.8 ± 3.4 | 45.7 ± 4.9 | 59.9 ± 5.9 | 54.3 ± 4.7 |
| dP/dtmin (mmHg/s) | − 9322 ± 542 | − 6677 ± 433* | − 11,095 ± 640 | − 6736 ± 598*** |
Statistical significance of post hoc test compared to same-sex control is highlighted as follows: *P < 0.05, **P < 0.01, ***P < 0.001. M-Co male control, M-Isch male ischemic, F-Co female control, F-Isch female ischemic, BW body weight, SABP systolic arterial blood pressure, DABP diastolic arterial blood pressure, HR heart rate 48 h after the first injection, LVESP left ventricular end-systolic pressure, LVEDP left ventricular end-diastolic pressure, LVEDV left ventricular end-diastolic volume, LVESV left ventricular end-systolic volume, SV stroke volume, CO cardiac output, SW stroke work, dP/dtmax maximal rate of rise in LV pressure, dP/dtmax-EDV maximal slope of dP/dtmax – EDV relationship, dP/dtmin maximal rate of decrease in LV pressure
Fig. 3Proteomic comparison of sex-specific changes after ischemia. A Results of differential expression analysis. Proteins under sex-specific regulation are highlighted. An adjusted P-value of < 0.05 was considered significant compared to the sex-matched control group. The female proteomic adaptation following ischemia is characterized by a higher number of upregulated proteins compared to males. B sPLS-DA analysis on the proteomes of all experimental groups. The supervised method clearly separated all groups, proving that both sex and ischemia affect proteomic profiles. C Proteins under sex-dependent regulation in response to ischemia were grouped according to biological categories. Statistically significant association was found between sex and differential expression of proteins with a function in transcription, inflammation, extracellular remodeling and cytoskeletal organization. Statistical significance of Fisher’s exact test is highlighted as follows: *P < 0.05, **P < 0.01, ***P < 0.001. M-Co: male control; M-Isch: male ischemic; F-Co: female control; F-Isch: female ischemic
Fig. 4Assessment of influence of circulating steroid hormone levels on functional outcomes after ischemia in females. A Hierarchical clustering identified two equally sized subgroups of female ischemic animals characterized by an overall mild or severe functional impairment based on parameters of the pressure–volume analysis. B PLS-DA analysis performed on the concentrations of circulating steroid hormone levels in ischemic females resulted in a moderate separation of animals with mild or severe functional outcomes. C Absolute concentrations of steroid hormones that were found influential on functional or proteomic profiles. D VIP scores extracted from the PLS-DA model identified hormones that contributed the most to the moderate separation of mild and severe functional outcomes. E–H Out of all influential hormones 2-OHE1 showed strong significant correlations with systolic (PRSW) and diastolic (Tau, dP/dtmin) as well as HW/TL. For comparison of functional and hormonal datasets acquired by distinct methodologies values were log-transformed and quantile normalized. M-Co: male control; M-Isch: male ischemic; F-Co: female control; F-Isch: female ischemic; SABP: systolic arterial blood pressure; DABP: diastolic arterial blood pressure; HR: heart rate; LVESP: left ventricular end-systolic pressure; LVEDP: left ventricular end-diastolic pressure; LVEDV: left ventricular end-diastolic volume; LVESV: left ventricular end-systolic volume; SV: stroke volume; CO: cardiac output; SW: stroke work; dP/dtmax maximal rate of rise in LV pressure; EF: ejection fraction; PRSW: preload recruitable stroke work; dP/dtmax-EDV: maximal slope of dP/dtmax – EDV relationship; Eff: cardiac efficiency; dP/dtmin: maximal rate of decrease in LV pressure; C1: component 1; C2: component 2; ALDO: aldosterone; PROG: progesterone; 2-OHE1: 2-hydroxyestrone, 4-OHE1: 4-hydroxyestrone; 4-MeE2: 4-methoxyestradiol; DHT: dihydrotestosterone; 2-MeE1: 2-methoxyestrone; 2-MeE2: 2-methoxyestradiol; 16-OHE1 + 16OE2: 16-hydroxyestrone + 16-ketoestradiol; E2: estradiol; CORT: corticosterone; DOC: 11-deoxycorticosterone; E1: estrone; HW/TL: heart weight normalized to tibia length
Fig. 5Gene ontology biological process enrichment analysis on proteins associated with hormone concentrations after ischemia in females. 2-OHE1: 2-hydroxyestrone; 4-OHE1: 4-hydroxyestrone; E2: estradiol